Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs

Table 1 Results of screening studies for long-term iVDPV excretion among individuals with PIDs

Country	Total patients with PIDs studied	CVID patients studied	Poliovirus excretors	iVDPV excretors	Patients with > 6 months of documented excretion	Source(s)
Bangladesh	13	0	1	0	0	[52]
Brazil	95	70	3	0	0	[16]
China	167	22	3	0	0	[52]
Egypt^a	15	3	2	0	0	[21]
Iran	43	16	1	0	0	[52]
Italy	38	0	0	0	0	[17]
Mexico	33	5	1	0	0	[16]
Philippines	70	6	1	0	0	[52, 60]
Russia	136	27	0	0	0	[52]
Sri Lanka	51	13	5	2	1^b	[20, 52]
Tunisia	16	2	4	0	0	[61]
Tunisia	82	14	6		0	[19, 52]
United Kingdom	125	65	0	0	0	[16]
United States	94	75	0	0	0	[16]
Total	978	318	27	2	1

ISSN: 1471-2334